Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -9 of 9 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		A Study to Provide Access to Trabectedin in Patients With Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				CR003583 SAR-3002, ET743SAR3002, NCT00210665


2.		A Study of Effectiveness of Trabectedin for the Treatment of Patient With Specific Subtypes of Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				CR014764 NCT00580112


3.		A Study of the Safety and Effectiveness of Trabetedin Versus Doxorubicin-Based Chemotherapy in Patients With Translocation-Related Sarcomas (TRS)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Approved-not yet active				18 and over				Pharmaceutical / Industry				CR015769 NCT00796120


4.		A Placebo-Controlled Study Evaluating the Potential Effects of Trabectedin on the Heart in Patients With Advanced Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Supportive care, Treatment				Active				18 to 65				Pharmaceutical / Industry				CR014917 NCT00786838

Last Modified: 1/14/2009 First Published: 9/24/2003


5.		Phase II Study of Ecteinascidin 743 in Pediatric Patients With Recurrent or Refractory Soft Tissue Sarcomas or Ewing's Sarcoma Family of Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				1 to 21 (at time of diagnosis)				NCI				COG-ADVL0221 NCT00070109, ADVL0221


6.		ET-743 in Men With Advanced Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Not specified				Pharmaceutical / Industry				ET-B-025-02 NCT00072670


7.		ET 743 (Yondelis) in Men With Advanced Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				02-061 NCT00147212


8.		A Study of the Safety and Effectiveness of Trabectedin for the Treatment of Localized Myxoid / Round Liposarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				CR014767 NCT00579501

Last Modified: 6/25/2008 First Published: 2/12/2007


9.		Phase I Study of Trabectedin in Pediatric Patients With Relapsed or Refractory Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				4 to 16				NCI				NCI-07-C-0054 NCT00437047

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute